Clinical trials: Endocrine Therapy
Pancreatic Cancer
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
The main purpose of this study is to look at the effectiveness, safety, and antitumor activity (preventing growth of the tumor) of the experimental study drug rucaparib (also known as CO-338) on subjects and on their pancreatic…
- Trial name
- NCT03140670
- Testing
- RUCAPARIB
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00382070
- Testing
- Letrozole
- Where
- 806 sites in United States, Canada and 1 more
- Volunteers
- 3,966 people
- Sponsor
- NSABP Foundation Inc
Polycystic Ovary Syndrome (PCOS), Overweight
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
Polycystic ovary syndrome (PCOS) is a health problem that affects one in 10 women of childbearing age, which is usually characterized by hormonal imbalance and metabolism problems such as hyperandrogenism and obesity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
- Trial name
- NCT03151005
- Testing
- Metformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Xinqiao Hospital of Chongqing
Diabetes Mellitus, Type 2
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment…
- Trial name
- NCT00500331
- Testing
- GSK189075, pioglitazone
- Where
- 136 sites in United States, Argentina and 17 more
- Volunteers
- 334 people
- Sponsor
- GlaxoSmithKline
Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
This randomized phase II trial studies how well temsirolimus with or without megestrol acetate and tamoxifen citrate works in treating patients with endometrial cancer that has spread to other places in the body and usually…
- Conditions
- Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer
- Trial name
- NCT00729586
- Testing
- Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate
- Where
- 108 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Type 2 Diabetes Mellitus
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes
This study in Germany is designed to compare the effects of twice-daily exenatide plus metformin and twice-daily premixed human insulin aspart plus metformin with respect to glycemic control, as measured by HbA1c, combined with…
- Trial name
- NCT00434954
- Testing
- exenatide twice daily (BID), premixed insulin aspart twice daily (BID)
- Where
- 39 sites in Germany
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Growth Hormone Deficiency
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects…
- Trial name
- OraGrowtH210 (NCT04614337)
- Testing
- LUM-201, rhGH Norditropin® pen (34 µg/kg)
- Where
- 43 sites in United States, Australia and 4 more
- Volunteers
- 104 people
- Sponsor
- Lumos Pharma
Diabetes, Diabetes Mellitus, Type 2
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of…
- Trial name
- LEAD-2 (NCT00318461)
- Testing
- liraglutide, metformin, glimepiride
- Where
- 190 sites in Argentina, Australia and 18 more
- Volunteers
- 1,091 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Ischemic Heart Disease
Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)
The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with…
- Trial name
- ACESO-IHD (NCT04776239)
- Testing
- 100 million Allogeneic Mesenchymal Human Stem Cells
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Joshua M Hare
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland.
- Conditions
- Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03002623
- Testing
- CUDC-907
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Kidney Disease, Secondary Hyperparathyroidism
Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous
The purpose of this study is to assess health-related Quality of Life (QoL) changes in participants with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT) undergoing hemodialysis and receiving paricalcitol…
- Trial name
- QUALITIZE (NCT01368042)
- Where
- 11 sites in Greece
- Volunteers
- 265 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Type 2 Diabetes
IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)
The purpose of this study is to learn whether there is a difference in the amount of time glucose (blood sugar) stays within a target range (glucose 70 - 180 mg/dl) when using either continuous glucose monitoring (CGM) or…
- Trial name
- IGNITE (NCT05516797)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- HealthPartners Institute
Pancreatic Cancer
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
This study will evaluate the role of Gemcitabine and Abraxane in the treatment of resectable and borderline-resectable pancreatic cancer by giving the chemotherapy before surgery.
- Trial name
- GAIN-1 (NCT01470417)
- Testing
- Chemotherapy, Chemotherapy + ChemoRadiotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Diabetic Foot Ulcer
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
The purpose of this study is to determine whether Garamycin Sponge (Gentamicin-Collagen sponge) in combination with antibiotics is safe and effective in treating moderate and severe diabetic foot infections.
- Trial name
- NCT01951768
- Testing
- Garamycin Sponge (Gentamicin-Collagen sponge), Systemic Antibiotic
- Where
- Switzerland
- Volunteers
- 88 people
- Sponsor
- University Hospital, Geneva
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy.
- Trial name
- NCT04055090
- Testing
- Long-Term Follow-Up of Patients who Received Engensis (VM202)
- Where
- 14 sites in United States
- Volunteers
- 101 people
- Sponsor
- Helixmith Co., Ltd.
Diabetes Mellitus, Type 2
Impact of Pharmacy Clinic on Diabetes Management
The Beaumont Hospital Royal Oak Outpatient Clinic (and other listed Beaumont recruiting locations) care for over 900 patients with diabetes.
- Trial name
- PharmaMD (NCT03377127)
- Testing
- Pharmacy Managed Diabetes Clinic (PMDC), Standard of Care (SOC)
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Corewell Health East
Diabetes Mellitus, Type 2, Coronary Artery Disease
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm.
- Trial name
- OPTIMUS-7 (NCT04484259)
- Testing
- Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type 2
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus.
- Trial name
- NCT01703286
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated…
- Trial name
- NCT00661362
- Testing
- Saxagliptin, Metformin
- Where
- 30 sites in China, India and 1 more
- Volunteers
- 570 people
- Sponsor
- AstraZeneca
Diabetic Foot Ulcers, Diabetic Foot Wounds
Wound Edge Changes Following Treatment With Santyl
The goal of this study is to evaluate changes in the healing tissue of diabetic foot wounds following 14 days of treatment with Santyl or its vehicle base.
- Trial name
- NCT01197898
- Testing
- Collagenase Santyl Ointment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Healthpoint